Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study

ConclusionThe addition of selexipag to background double combination therapy with an ERA and PDE-5i provides an incremental benefit similar to that seen in the overall population, including in patients with WHO FC II or III symptoms at baseline.ClinicalTrials.gov IdentifierNCT01106014.

Source: American Journal of Cardiovascular Drugs - January 6, 2018 Category: Cardiology Source Type: research